187.55 -1.61 (-0.85%)
After hours: 4:11PM EDT
|Bid||189.45 x 800|
|Ask||189.60 x 800|
|Day's Range||184.43 - 190.46|
|52 Week Range||132.75 - 206.04|
|Beta (3Y Monthly)||1.59|
|PE Ratio (TTM)||75.79|
|Earnings Date||Apr 30, 2019|
|Forward Dividend & Yield||1.28 (0.64%)|
|1y Target Est||201.14|
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Bio-Techne Corporation (NASDAQ...
Bio-Techne Corp NASDAQ/NGS:TECHView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for TECH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting TECH. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding TECH are favorable with net inflows of $71.37 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
MINNEAPOLIS , April 9, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, April 30, 2019 at 8:00 a.m. CDT to review third ...
[Editor's note: This story was previously published in July 2018. It has since been updated and republished.]First, let's get something straight. The definition of penny stocks is entirely subjective. What I think constitutes a risky penny stock, you might feel is a robust, thriving enterprise. Therefore, before I answer the question of whether you can make money in penny stocks, I'm going to explain what I believe is the best definition of a penny stock. From there, I'll tackle the five rules investors should follow to be successful in trading penny stocks.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The Elite 8 Stocks to Buy for Massive Outperformance The Definition: Merriam-Webster defines penny stock as "a usually unlisted highly speculative stock usually selling for a dollar or less." Hence, the penny-stock moniker. Others are more liberal in their interpretation of what constitutes a penny stock.The Successful Investor, an investment newsletter publisher I do some work for here in Canada, suggests the ceiling price can go as high as $5. Here's what the SEC has to say about penny stocks:"The term 'penny stock' generally refers to a security issued by a very small company that trades at less than $5 per share," states the SEC website. "Penny stocks generally are quoted over-the-counter, such as on the OTC Bulletin Board; penny stocks may, however, also trade on securities exchanges, including foreign securities exchanges."So, I've got reputable sources from both the U.S. and Canada who accurately define what penny stocks are, including the price at which they trade.At $5 or less, I do believe you can make money in stocks, but it helps if you follow these five simple rules.For every success story like Monster Beverage (NASDAQ:MNST), which traded below $5 as recently as 2006, there are hundreds of penny stock failures littered along the investment highway. * The Elite 8 Stocks to Buy for Massive Outperformance Treat penny stocks just as you would any other publicly traded investment, and your chances for success increase exponentially. Tip 1: Buy Companies With Strong Balance SheetsLike any equity investment, it's important that you establish the financial strength of the company. When I look for stocks to invest in whether the share price is $5 or $500, I focus on companies with strong balance sheets. Although no debt is desirable when interest rates are rising, it's not very practical. This is especially true when it comes to penny stocks, many of which are still in the early stages of development. Here are two rules:1\. Only invest in companies whose long-term debt (LTD) is 50% of shareholder equity or less. If a company has $1 million in debt, its shareholder equity should be at least $2 million. 2\. Try to keep your penny-stock bets to those companies whose LTD is less than its market cap; the lower, the better. Tip 2: Buy Profitable CompaniesAs with any equity investment, it's important that you limit your investments to profitable businesses. There are two schools of thought on this. On the one hand, investing in publicly-traded companies, whether they're penny stocks or not, provides you with greater liquidity than private investments. Therefore, the ability to exit quicker justifies the higher risk many in this arena are willing to accept to generate outsize future gains. On the other hand, private investments have longer holding periods built into them -- often 3-5 years or more -- which means investors aren't nearly as concerned about profitability as they are with growth. It really comes down to your ability to handle uncertainty. For me, I'm always looking for companies making money in the here and now. Anything less is called speculation, and while there's nothing wrong with this approach, it's not something novice investors ought to consider. Tip 3: Understand the BusinessLike any equity investment, it's important that you understand the businesses you invest in. There's a saying that if you can't explain what a company's business does in a sentence or two, you probably shouldn't be investing.Imagine you're explaining the investment to your child who attends elementary school. It's easy to describe what Coca-Cola (NYSE:KO) does: it makes soda pop. It's not nearly as simple to describe what business Bio-Techne (NASDAQ:TECH) is in.At least it's not for me. Stick to what you know and understand. That's especially true with penny stocks with smaller market caps. Tip 4: Diversify Like any equity investment, it's important that you diversify your penny stocks. How many penny stocks should you own? That's the million-dollar question, no matter how big or small the investment. Some professional investors believe you've got to have a concentrated portfolio of your best ideas -- say 10 to 20 -- while others think you should spread your bets far wider over 100 stocks or more. It's a subjective answer for sure. What I do know is that you want to be in at least three or four sectors of the economy that generally are healthy and growing.Since the risk/reward ratio of penny stocks can be significantly higher than that of large-cap stocks such as Coca-Cola, it's far more important to diversify your investments. Tip 5: Risk What You Can Afford to LoseLike any equity investment, it's important that you understand there are no guarantees and that you're risking the money you can afford to lose.If your child's going off to university in a couple of years and the funds you've allocated for investing will pay his or her tuition, you might want to keep your funds parked in something more stable.As of this writing, Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Tech Stocks That Transformed Their Business * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos * 7 Weak Blue-Chip Stocks to Trim Immediately Compare Brokers The post 5 Tips for Making Money in Penny Stocks appeared first on InvestorPlace.
-- Integrated Workflow Combines NanoString's GeoMx DSP High-Plex RNA Assays and Bio-Techne's Highly Sensitive RNAscope Imaging Reagent Portfolio -- MINNEAPOLIS , March 28, 2019 /PRNewswire/ -- Bio-Techne ...
MINNEAPOLIS , March 5, 2019 /PRNewswire/ -- Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, was honored ...
MINNEAPOLIS , March 5, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Jim Hippel , Chief Financial Officer will present at the Barclays Global Healthcare Conference on Wednesday, ...
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
MINNEAPOLIS, Feb. 26, 2019 /PRNewswire/ -- Bio-Techne has entered into a strategic cooperation agreement in the precision medicine field with Lisen Imprinting Diagnostics Wuxi Co., Ltd, China. Liwen Pei, Managing Director of Bio-Techne China, and Ning Zhou, CEO of Lisen, attended the meeting and signing ceremony. Bio-Techne is a leading provider of high-quality consumables and instruments for the life science and molecular diagnostic markets.
MINNEAPOLIS , Feb. 20, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer will present at the 8 th Annual SVB Leerink Global ...
Techne (TECH) delivered earnings and revenue surprises of 6.00% and 2.57%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
MINNEAPOLIS , Feb. 5, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2018 . Second Quarter FY2019 Snapshot Second ...
MINNEAPOLIS , Feb. 5, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, ...
Want to help shape the future of investing tools? Participate in a short research study and receive a subscription valued at $60. One of the best investments we can make Read More...
MINNEAPOLIS, Jan. 31, 2019 /PRNewswire/ -- Bio-Techne Corporation (TECH) today announced the National Comprehensive Cancer Network (NCCN) decision to include EPI as a recommended test in their Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection (Version 1.2019). The updated treatment algorithm includes EPI testing prior to a first prostate biopsy or after a negative biopsy to assist patients and urologists in further defining the probability of high-grade cancer and in reaching a joint decision to either proceed with a prostate biopsy or continue monitoring.
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Every now and then, a stock seemingly explodes out of nowhere. Right now, Avalon GloboCare (NASDAQ:AVCO) seems to be that stock. AVCO stock finished 2018 at $2.75. That same Avalon GloboCare stock closed Monday at $6.93, after touching $12 last week. Source: Shutterstock It's not at all clear what's driving the huge gains. Indeed, Will Healy wrote last week that the movement in AVCO stock was a mystery. There is an apparently interesting opportunity in the company's efforts in the exosome space. But questions surround how the company is attacking that opportunity -- and why investors value AVCO at some $500 million. InvestorPlace - Stock Market News, Stock Advice & Trading Tips ### The AVCO Stock Story Avalon Globocare was incorporated as Global Technologies, and issued its first Form 10-K in February 2016. At the time, the company had 7 million shares outstanding and zero employees. The K cites a plan to develop back office software, which sounds roughly like the business model of Square (NYSE:SQ). * 7 High-Dividend Stocks Yielding More Than 5% (Plus a Bonus) In 2016, the company executed a reverse split and changed its name to Avalon GloboCare. The company that was a software developer now had a multi-pronged medical strategy. AVCO would develop an "Avalon cell" platform, with four different programs. One was a focus on CAR-T immunotherapy; remember that Gilead Sciences (NASDAQ:GILD) bought CAR-T leader Kite Pharma for $12 billion last year. Beyond "Avalon cell," AVCO also noted a potential telemedicine opportunity, and a rehabilitation offering in China. And it cited the potential for M&A, joint venture and consulting opportunities. Last year, the company acquired 60% of GenExosome Technologies for $1.3 million in cash and 500,000 shares. It also acquired property in New Jersey, with rental income contributing to revenue, along with consulting. And this week, GenExosome announced the discovery of the "world's first saliva-based exosomal biomarker," which potentially could be used in detecting and treating oral cancer. If that pans out, the opportunities could be huge, so it does seem like Avalon GloboCare is making some progress. But there are some very real questions here. ### Strategic Questions for Avalon GloboCare The most obvious question surrounding AVCO stock is why, exactly, the company is supposed to be successful. This is a company that closed the third quarter with $3.8 million in cash. That's barely enough to support any of the company's initiatives: indeed, the company has free cash flow of negative $3.6 million in just the first three quarters of this year, per the 10-Q. So why the multiple efforts? And what is Avalon GloboCare's edge in any of them? Meanwhile, the strategy per the most recent 10-K seems to go even further. The company cites an "initial component" of its strategy as "acquiring and/or managing fixed assets including healthcare real estate as well as stem cell banks." This comes after the company - which, again, has less than $4 million in cash - spent over $7 million to purchase, rather than lease, its New Jersey headquarters. The overall strategy here seems unfocused, to say the least. Is the company a consulting firm? A real estate management company? A drug developer? It's not clear. To be sure, Exosome technology in theory has promise: one analyst called the category "the rising star in drug delivery." And Bio-Techne (NASDAQ:TECH) paid $250 million in cash, plus contingent consideration, for Exosome Diagnostics last year. But Avalon GloboCare doesn't even seem to be focusing on that opportunity. And a company that does many things isn't likely to do any of them well. Meanwhile, with less than $4 million in cash, there clearly isn't enough to properly support any of these efforts. That means an AVCO stock offering likely is on the way. But it also suggests that Avalon GloboCare stock could be notably overvalued. ### The Valuation of Avalon GloboCare Stock It's impossible to evaluate AVCO stock through pure fundamental analysis. Revenue outside of property rental is just $370,000 so far this year. But what figures we do have suggest that a stock price near $7 is somewhat foolish. The 60% stake in GenExosome was acquired for $1.3 million in cash and roughly $1 million worth of stock. If that business is driving the recent optimism, why was such a valuable business sold for an implied valuation of $4 million? Avalon GloboCare itself sold stock last year -- at $1.75 and $2.25. Even acknowledging that small-cap companies have to execute offerings at a substantial discount, Avalon GloboCare issued stock at barely one-fourth the current price. Between M&A and the equity offering, nothing AVCO itself has done suggests that the company believes it should be worth roughly $500 million. That's the current market capitalization of AVCO, based on the quarter-end figure of 72.573 million shares outstanding. Investors should note that AVCO -- which hasn't really accomplished anything, and which has significant financial and strategic questions -- now is worth more than Exosome Technologies when it was bought out, even accounting for the present value of the contingent consideration. That seems aggressive for a company with basically one accomplishment of note. That's particularly true given that as recently as 2015 the company was trying to develop software. How the rest of this story will play out is unclear, admittedly. But it does seem already like the absolute best-case scenario is priced in. As of this writing, Vince Martin had no positions in any securities mentioned. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy With High ESG Momentum * 7 Chinese Stocks to Buy Now * 5 Dow Jones Stocks Under Pressure Compare Brokers The post Avalon GloboCare Stock Is an Expensive Mystery appeared first on InvestorPlace.
MINNEAPOLIS , Jan. 29, 2019 /PRNewswire/ -- Bio-Techne today announced the launch of a new customizable cartridge format for their ProteinSimple-branded Ella™ immunoassay platform. Ella allows users to ...